Pleryon Therapeutics is a preclinical stage biotech startup company. Our mission is to develop novel polymer-based therapeutics to address global unmet medical needs related to aging. Since its formal operation in 2020, Pleryon has raised closed to RMB 100 million from top biotech private investors. Pleryon is advancing its diverse pipelines in multiple disease areas, including ophthalmology, orthopedics, and tissue regeneration.
Company Details
- Employees
- 6
- Founded
- -
- Address
- Yesun Intelligent Community, 1301-72 Guanguang Rd., Longhua, Shenzhen,guangdong 518000,china
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- pleryon.com
- HQ
- Shenzhen, Guangdong
Pleryon Therapeutics Questions
Pleryon Therapeutics's website is pleryon.com
Pleryon Therapeutics's LinkedIn profile is https://cn.linkedin.com/company/pleryon
Pleryon Therapeutics has
6 employees.
View email and phone details for 6
employees at Pleryon Therapeutics.
Pleryon Therapeutics's industry is
Biotechnology Research
Pleryon Therapeutics's top competitors are
Liberyx Therapeutics,
Ssygroup,
Allegrow Biotech,
Genentech,
Moderna,
Regent Pacific Group(Hk)ltd.,
Amneal Pharmaceuticals,
Amgen,
Opharmic Technology,
Pentsao Fund Lp.
Pleryon Therapeutics's categories are Biotechnology Research
Pleryon Therapeutics's founding year is 2017
